BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024GlobeNewsWire • 10/24/24
BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific SessionsGlobeNewsWire • 10/03/24
BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart DiseaseBenzinga • 09/30/24
BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)GlobeNewsWire • 09/30/24
BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization EventsGlobeNewsWire • 09/27/24
BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDAGlobeNewsWire • 09/17/24
BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)GlobeNewsWire • 09/10/24
BridgeBio Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy ProgramGlobeNewsWire • 09/10/24
BridgeBio Oncology Therapeutics (BBOT) Announces the Appointment of Yong Ben, MD, as Chief Medical and Development OfficerBusiness Wire • 09/09/24
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 09/06/24
BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of AcoramidisSeeking Alpha • 08/31/24
BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label ExtensionGlobeNewsWire • 08/30/24
BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024GlobeNewsWire • 08/29/24
BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial IntelligenceGlobeNewsWire • 08/26/24
BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating AchondroplasiaGlobeNewsWire • 08/19/24
BridgeBio Pharma's Acoramidis Leads Promising Pipeline With FDA Approval On HorizonSeeking Alpha • 08/17/24
BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/01/24
BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business UpdateGlobeNewsWire • 08/01/24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIOGlobeNewsWire • 07/26/24
BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating OfficerGlobeNewsWire • 07/23/24